Korea leukemia patients organization launched a one-man protest, urging the first C-ART treatment Kymriah (Tisagencleucel)'s fast track.

The Korea Leukemia Association held a press conference in front of the National Human Rights Commission of Korea at 10 a.m. on the 1st and announced that it submitted a petition to the National Human Rights Commission of Korea demanding Kymriah's health insurance registration and fast track for new drugs. Kymriah is the world's first chimera antigen receptor T-cell treatment that is effective in treating patients with recurrent or refractory B-cell acute lymphocytic leukemia and refractory giant B-cell lymphoma.

Although patients are expected to have an